1. Home
  2. MITQ vs SNOA Comparison

MITQ vs SNOA Comparison

Compare MITQ & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moving iMage Technologies Inc.

MITQ

Moving iMage Technologies Inc.

HOLD

Current Price

$0.65

Market Cap

7.4M

ML Signal

HOLD

Logo Sonoma Pharmaceuticals Inc.

SNOA

Sonoma Pharmaceuticals Inc.

HOLD

Current Price

$3.57

Market Cap

6.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MITQ
SNOA
Founded
N/A
1999
Country
United States
United States
Employees
N/A
168
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4M
6.1M
IPO Year
2021
2007

Fundamental Metrics

Financial Performance
Metric
MITQ
SNOA
Price
$0.65
$3.57
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
54.0K
27.2K
Earning Date
11-14-2025
02-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$18,477,000.00
$16,937,000.00
Revenue This Year
N/A
$23.00
Revenue Next Year
N/A
$24.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
25.02
52 Week Low
$0.50
$1.75
52 Week High
$1.66
$6.92

Technical Indicators

Market Signals
Indicator
MITQ
SNOA
Relative Strength Index (RSI) 38.04 52.28
Support Level $0.65 $3.25
Resistance Level $0.73 $3.95
Average True Range (ATR) 0.04 0.29
MACD -0.00 0.03
Stochastic Oscillator 4.21 55.56

Price Performance

Historical Comparison
MITQ
SNOA

About MITQ Moving iMage Technologies Inc.

Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.

About SNOA Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Share on Social Networks: